Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Summary

The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.

Timeline

Start

2024-09-20

Primary completion

2025-10-09

Completion

2025-10-09

Outcome

Met primary endpoint

release “The NAVIGATE study met all primary and secondary endpoints associated with preventing symptomatic laboratory-confirmed influenza in healthy unvaccinated adults ages 18 to 64.” merck.com ↗

Drugs

Indications